The ratio of eicosapentaenoic acid to arachidonic acid is a critical risk factor for acute coronary syndrome in middle-aged older patients as well as younger adult patients

Journal of Cardiology

Volumn 63, Issue 1, 2014, Pages 35-40

  Serikawa, Takeshi ^a   Miura, Shin ichiro ^b   Okabe, Masanori ^a   Hongo, Hiroshi ^a   Tokutome, Masaki ^a   Yoshikawa, Tomoko ^a   Takesue, Ko ^a   Adachi, Sen ^a   Osaka, Kunpei ^a   Matsukawa, Ryuichi ^a   Yanagi, Daizaburo ^a   Nozoe, Masatsugu ^a   Kozai, Toshiyuki ^a   Hironaga, Kiyoshi ^a   Saku, Keijiro ^b   Yamamoto, Yusuke ^a  

^a Saiseikai Fukuoka Hospital   (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute coronary syndrome; Coronary angiography; Docosahexaenoic acid; Eicosapentaenoic acid; Polyunsaturated fatty acids

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ARACHIDONIC ACID; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; THIENOPYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; SMOKING;

ACUTE CORONARY SYNDROME; CORONARY ANGIOGRAPHY; DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; POLYUNSATURATED FATTY ACIDS;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ARACHIDONIC ACID; ASPIRIN; CALCIUM CHANNEL BLOCKERS; CHOLESTEROL, HDL; CORONARY ANGIOGRAPHY; DRUGS, CHINESE HERBAL; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; SMOKING;

EID: 84891900950     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.06.016     Document Type: Article

References (50)

1. Statistics and Information Department Vital statistics 2011 2012, Ministry of Health, Labor and Welfare, Tokyo.
2. Turin T.C., Kokubo Y., Murakami Y., Higashiyama A., Rumana N., Watanabe M., Okamura T. Lifetime risk of acute myocardial infarction in Japan. Circ Cardiovasc Qual Outcomes 2010, 3:701-703.
3. Maruyama M., Ohira T., Imano H., Kitamura A., Kiyama M., Okada T., Maeda K., Yamagishi K., Noda H., Ishikawa Y., Shimamoto T., Iso H. Trends in sudden cardiac death and its risk factors in Japan from 1981 to 2005: the Circulatory Risk in Communities Study (CIRCS). BMJ Open 2012, 2:e000573.
4. Joensen A.M., Schmidt E.B., Dethlefsen C., Johnsen S.P., Tiooneland A., Rasmussen L.H., Overvad K. Dietary intake of total marine n-3 polyunsaturated fatty acids, eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid and the risk of acute coronary syndrome - a cohort study. Br J Nutr 2010, 103:602-607.
5. Joensen A.M., Overvad K., Dethlefsen C., Joensen S.P., Tiooneland A., Rasmussen L.H., Schmidt E.B. Marine n-3 polyunsaturated fatty acids in adipose tissue and the risk of acute coronary syndrome. Circulation 2011, 124:1232-1238.
6. Bjerregaard L.J., Joensen A.M., Dethlefsen C., Jensen M.K., Johnsen S.P., Tjønneland A., Rasmussen L.H., Overvad K., Schmidt E.B. Fish intake and acute coronary syndrome. Eur Heart J 2010, 31:29-34.
7. Cottin S.C., Sanders T.A., Hall W.L. The differential effects of EPA and DHA on cardiovascular risk factors. Proc Nutr Soc 2011, 70:215-231.
8. Kuzuya T., Nakagawa S., Satoh J., Kanazawa Y., Iwamoto Y., Kobayashi M., Nanjo K., Sasaki A., Seino Y., Ito C., Shima K., Nonaka K., Kadowaki T. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002, 55:65-85. Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus.
9. Alpert J.S., Thygesen K., Antman E., Bassand J.P. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000, 36:959-969.
10. Hamm C.W., Braunwald E. A classification of unstable angina revisited. Circulation 2000, 102:118-122.
11. Kashiyama T., Ueda Y., Nemoto T., Wada M., Masumura Y., Matsuo K. Relationship between coronary plaque vulnerability and serum n-3/n-6 polyunsaturated fatty acid ratio. Circ J 2011, 75:2432-2438.
12. Hu F.B., Bronner L., Willett W.C., Stampfer M.J., Rexrode K.M., Albert C.M., Hunter D., Manson J.E. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002, 287:1815-1821.
13. Wang C., Harris W.S., Chung M., Lichtenstein A.H., Balk E.M., Kupelnick B., Jordan H.S., Lau J. n-3 fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr 2006, 84:5-17.
14. Kris-Etherton P.M., Harris W.S., Appel L.J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757. American Heart Association. Nutrition Committee.
15. Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Saito Y., Ishikawa Y., Oikawa S., Sasaki J., Hishida H., Itakura H., Kita T., Kitabatake A., Nakaya N., Sakata T., Shimada K., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
16. Lee S.H., Shin M.J., Kim J.S., Ko Y.G., Kang S.M., Choi D., Jang Y., Chung N., Shim W.H., Cho S.Y., Manabe I., Ha J.W. Blood eicosapentaenoic acid and docosahexaenoic acid as predictors of all-cause mortality in patients with acute myocardial infarction - data from Infarction Prognosis Study (IPS) Registry. Circ J 2009, 73:2250-2257.
17. Domei T., Yokoi H., Kuramitsu S., Soga Y., Arita T., Ando K., Shirai S., Kondo K., Sakai K., Goya M., Iwabuchi M., Ueeda M., Nobuyoshi M. Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. Circ J 2012, 76:423-429.
18. Nozue T., Yamamoto S., Tohyama S., Fukui K., Umezawa S., Onishi Y., Kunishima T., Sato A., Nozato T., Miyake S., Takeyama Y., Morino Y., Yamauchi T., Muramatsu T., Hibi K., et al. Effects of serum n-3 to n-6 polyunsaturated fatty acids ratios on coronary atherosclerosis in statin-treated patients with coronary artery disease. Am J Cardiol 2013, 111:6-11.
19. Eslick G.D., Howe P.R., Smith C., Priest R., Bensoussan A. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol 2009, 136:4-16.
20. Rupp H., Wagner D., Rupp T., Schulte L.M., Maisch B. Risk stratification by the "EPA+DHA level" and the "EPA/AA ratio" focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids. Herz 2004, 29:673-685.
21. Wang D., Hirase T., Nitto T., Soma M., Node K. Eicosapentaenoic acid increases cytochrome P-450 2J2 gene expression and epoxyeicosatrienoic acid production via peroxisome proliferator-activated receptor gamma in endothelial cells. J Cardiol 2009, 54:368-374.
22. Russell F.D., Bürgin-Maunder C.S. Distinguishing health benefits of eicosapentaenoic and docosahexaenoic acids. Mar Drugs 2012, 10:2535-2559.
23. Dyerberg J., Bang H.O., Stoffersen E., Monaca S., Vane J.R. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosisα. Lancet 1978, 2:117-119.
24. Krämer H.J., Stevens J., Grimminger F., Seeger W. Fish oil fatty acids and human platelets: dose-dependent decrease in dienoic and increase in trienoic thromboxane generation. Biochem Pharmacol 1996, 52:1211-1217.
25. Zampelas A. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 2010, 212:34-35.
26. Thies F., Garry J.M., Yaqoob P., Rerkasem K., Williams J., Shearman C.P., Gallagher P.J., Calder P.C., Grimble R.F. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003, 361:477-485.
27. Holub B.J. Docosahexaenoic acid (DHA) and cardiovascular disease risk factors. Prostaglandins Leukot Essent Fatty Acids 2009, 81:199-204.
28. Davidson M.H., Maki K.C., Kalkowski J., Schaefer E.J., Torri S.A., Drennan K.B. Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial. J Am Coll Nutr 1997, 16:236-243.
29. Leigh-Firbank E.C., Minihane A.M., Leake D.S., Wright J.W., Murphy M.C., Griffin B.A., Williams C.M. Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses. Br J Nutr 2002, 87:435-445.
30. Itakura H., Yokoyama M., Matsuzaki M., Saito Y., Origasa H., Ishikawa Y., Oikawa S., Sasaki J., Hishida H., Kita T., Kitabatake A., Nakaya N., Sakata T., Shimada K., Shirato K., et al. The change in low-density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid. J Atheroscler Thromb 2012, 19:673-679.
31. Lee S.H., Shin M.J., Kim J.S., Ko Y.G., Kang S.M., Choi D., Jang Y., Chung N., Shim W.H., Cho S.Y., Manabe I., Ha J.W. Blood eicosapentaenoic acid and docosahexaenoic acid as predictors of all-cause mortality in patients with acute myocardial infarction: data from Infarction Prognosis Study (IPS) Registry. Circ J 2009, 73:2250-2257.
32. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
33. Ono K. Current concept of reverse cholesterol transport and novel strategy for atheroprotection. J Cardiol 2012, 60:339-343.
34. Jafri H., Alsheikh-Ali A.A., Karas R.H. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 2010, 55:2846-2854.
35. Steering Committee of the Physicians' Health Study Research Group Final report on the Aspirin Component of the Ongoing Physicians' Health Study. N Engl J Med 1989, 321:129-135.
36. Hayden M., Pignone M., Phillips C., Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002, 136:161-172.
37. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
38. Gerstein H.C., Miller M.E., Genuth S., Ismail-Beigi F., Buse J.B., Goff D.C., Probstfield J.L., Cushman W.C., Ginsberg H.N., Bigger J.T., Grimm R.H., Byington R.P., Rosenberg Y.D., Friedewald W.T. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011, 364:818-828. ACCORD Study Group.
39. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., Cushman W.C., Genuth S., Ismail-Beigi F., Grimm R.H., Probstfield J.L., Simons-Morton D.G., Friedewald W.T. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. Action to Control Cardiovascular Risk in Diabetes Study Group.
40. Park J.Y., Rha S.W., Poddar K.L., Ramasamy S., Chen K.Y., Li Y.J., Choi B.G., Ryu S.K., Choi J.W., Park S.H., Park S., Elnagar A., Im S.I., Kim S.W., Na J.O., et al. Impact of low-dose aspirin on coronary artery spasm as assessed by intracoronary acetylcholine provocation test in Korean patients. J Cardiol 2012, 60:187-191.
41. Wakabayashi K., Suzuki H., Honda Y., Wakatsuki D., Kawachi K., Ota K., Koba S., Shimizu N., Asano F., Sato T., Takeyama Y. Provoked coronary spasm predicts adverse outcome in patients with acute myocardial infarction: a novel predictor of prognosis after acute myocardial infarction. J Am Coll Cardiol 2008, 52:518-522.
42. Capodanno D., Angiolillo D.J. Antithrombotic therapy in the elderly. J Am Coll Cardiol 2010, 56:1683-1692.
43. Brandes R.P., Fleming I., Busse R. Endothelial aging. Cardiovasc Res 2005, 66:286-294.
44. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001, 88:756-762.
45. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcome in patients with non insulin dependent diabetes and hypertension. N Engl J Med 1998, 338:645-652.
46. Tatti P., Pahor M., Byington R.P., Di Mauro P., Guarisco R., Strollo G., Strollo F. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:597-603.
47. Yusef S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin converting enzyme inhibitor, ramipril on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
48. Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I., Schumacher H., Dagenais G., Sleight P., Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559. ONTARGET Investigators.
49. Teo K.K., Ounpuu S., Hawken S., Pandey M.R., Valentin V., Hunt D., Diaz R., Rashed W., Freeman R., Jiang L., Zhang X., Yusuf S. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006, 368:647-658. INTERHEART Study Investigators.
50. Satoh S., Omura S., Inoue H., Mori T., Takenaka K., Numaguchi K., Mori E., Aso A., Nakamura T., Hiyamuta K. Clinical impact of coronary artery spasm in patients with no significant coronary stenosis in acute coronary syndromes. J Cardiol 2013, 61:404-409.